Author: Ken Dropiewski

CryoLife Reports Preliminary Financial Results for Third Quarter 2018 in Anticipation of Discussions with Senior Lenders Regarding Repricing Senior Credit Facility

ATLANTA, Oct. 15, 2018 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, in anticipation of discussions with its senior lenders regarding repricing its senior secured credit facility, today announced certain preliminary unaudited financial results for the third quarter of 2018. Preliminary and unaudited revenue […]

Penumbra, Inc. Schedules Third Quarter 2018 Earnings Release and Conference Call for November 5, 2018

ALAMEDA, Calif., Oct. 15, 2018 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2018 after market close on Monday, November 5, 2018 at 5:00 PM Eastern Time. A press release with third quarter 2018 financial results will be issued after market […]

Abbott Names Robert B. Ford President, Chief Operating Officer

ABBOTT PARK, Ill., Oct. 15, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today that Robert B. Ford has been named president and chief operating officer, effective immediately. Mr. Ford, a 22-year Abbott veteran, was most recently executive vice president of Medical Devices, Abbott’s largest business. In addition to his current responsibilities for Medical Devices, Mr. Ford, 45, […]

Bluegrass Vascular Announces Enrollment Completion Of International Post-Market SAVE Registry With Early Positive Results

SAN ANTONIO, Oct. 15, 2018 /PRNewswire/ — Bluegrass Vascular Technologies (Bluegrass Vascular), a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today it has successfully completed enrollment of its prospective, multicenter, post-CE Mark, international SAVE (Surfacer® System to Facilitate Access in VEnous Occlusions) Registry. In addition, the company […]

NobleStitch™ EL Again Expands Global Base With New Center In Ireland

BELFAST, Ireland, Oct. 11, 2018 /PRNewswire/ — NMT2 is excited to announce its expansion of NobleStitch™ EL into the Irish market with first series of PFO closure cases in Belfast, Ireland.  Dr. Mark Spence MD, Interventional Cardiologist and co-founder of the Structural Heart Disease Program at Belfast Health and Social Care Trust in Belfast successfully performed the first procedures […]

Micro Interventional Devices, Inc.™ Successfully Treats First-in-Human Patient with Percutaneous MIA™, Minimally Invasive Annuloplasty Technology

NEWTOWN, Pa., Oct. 12, 2018 /PRNewswire/ — Micro Interventional Devices, Inc.™ (MID) announced today the world’s first percutaneous implantation of its MIA™, Minimally Invasive Annuloplasty, technology for tricuspid and mitral repair.  This marks the first patient enrolled in the transcatheter arm of the STTAR (Study of Transcatheter Tricuspid Annular Repair) trial being conducted in Europe. […]

Bardy Diagnostics™ awarded Innovative Technology Contract with Vizient, Inc. for the Carnation Ambulatory Monitor™

SEATTLE, Oct. 11, 2018 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it was awarded an Innovative Technology contract with Vizient, Inc. for the Carnation Ambulatory Monitor (“CAM™”), the world’s first P-wave centric™ ambulatory cardiac patch monitor and arrhythmia […]

Geneva Health Solutions Launches Geneva University

NEW YORK–(BUSINESS WIRE)–Geneva Health Solutions (GHS), the leading cloud-based technology platform and service for managing data from implantable cardiac devices, has formalized its internal training systems by launching Geneva University, a business unit within GHS. Geneva University will be focused on the continuous improvement of all clinical and administrative processes. “Implantable […]

Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares

MONTRÉAL, Oct. 11, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced today the closing of its previously announced underwritten public offering […]